Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

UCB begins phase III Cimzia trial

Feb. 23, 2012

FDA accepts Actemra sBLA for review

Feb. 21, 2012

BioMarin begins clinical testing of achondroplasia candidate

Feb. 17, 2012

UCB planning regulatory applications for Cimzia in new indication

Feb. 17, 2012

Novel MAP kinase p38 alpha inhibitors synthesized at Amgen

Feb. 17, 2012

TiGenix's study of Cx-611 in rheumatoid arthritis cleared to open final cohort

Feb. 1, 2012

Astellas and UCB sign Japanese development and commercialization agreement for Cimzia

Feb. 1, 2012

Alantos identifies potent disease-modifying candidate osteoarthritis drug

Jan. 20, 2012

Protalex advances phase Ib study of PRTX-100

Jan. 19, 2012

BioMimetic Therapeutics receives response to Augment Bone Graft PMA

Jan. 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...